Rockefeller Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.4M | Sell |
21,563
-6,957
| -24% | -$4.74M | 0.02% | 616 |
|
|
2026
Q1 | $22M | Buy |
28,520
+1,467
| +5% | +$1.12M | 0.04% | 420 |
|
|
2025
Q4 | $20.9M | Buy |
27,053
+1,211
| +5% | +$822K | 0.04% | 431 |
|
|
2025
Q3 | $14.5M | Sell |
25,842
-3,778
| -13% | -$2.14M | 0.03% | 516 |
|
|
2025
Q2 | $15.6M | Sell |
29,620
-37,988
| -56% | -$21.2M | 0.03% | 461 |
|
|
2025
Q1 | $42.9M | Sell |
67,608
-27,136
| -29% | -$18.7M | 0.11% | 193 |
|
|
2024
Q4 | $67.5M | Sell |
94,744
-3,260
| -3% | -$2.74M | 0.17% | 120 |
|
|
2024
Q3 | $103M | Sell |
98,004
-1,096
| -1% | -$1.22M | 0.28% | 80 |
|
|
2024
Q2 | $104M | Sell |
99,100
-5,601
| -5% | -$5.43M | 0.3% | 73 |
|
|
2024
Q1 | $101M | Sell |
104,701
-910
| -0.9% | -$865K | 0.29% | 79 |
|
|
2023
Q4 | $92.8M | Buy |
105,611
+1,600
| +2% | +$1.32M | 0.31% | 76 |
|
|
2023
Q3 | $85.6M | Buy |
104,011
+25,319
| +32% | +$19.9M | 0.33% | 74 |
|
|
2023
Q2 | $56.5M | Buy |
78,692
+3,233
| +4% | +$2.49M | 0.22% | 109 |
|
|
2023
Q1 | $62M | Sell |
75,459
-27
| -0% | -$20.4K | 0.27% | 93 |
|
|
2022
Q4 | $54.5M | Sell |
75,486
-5,424
| -7% | -$4M | 0.27% | 88 |
|
|
2022
Q3 | $55.7M | Sell |
80,910
-839
| -1% | -$528K | 0.29% | 81 |
|
|
2022
Q2 | $48.3M | Sell |
81,749
-9,903
| -11% | -$6.44M | 0.26% | 87 |
|
|
2022
Q1 | $64M | Buy |
91,652
+5,492
| +6% | +$3.47M | 0.31% | 74 |
|
|
2021
Q4 | $54.4M | Sell |
86,160
-1,174
| -1% | -$722K | 0.25% | 94 |
|
|
2021
Q3 | $52.9M | Sell |
87,334
-102,416
| -54% | -$63.6M | 0.28% | 79 |
|
|
2021
Q2 | $106M | Buy |
189,750
+62,498
| +49% | +$31.7M | 0.6% | 32 |
|
|
2021
Q1 | $60.2M | Buy |
127,252
+18,631
| +17% | +$9.07M | 0.41% | 50 |
|
|
2020
Q4 | $52.5M | Buy |
108,621
+4,041
| +4% | +$2.18M | 0.4% | 58 |
|
|
2020
Q3 | $58.5M | Sell |
104,580
-27,219
| -21% | -$16.5M | 0.55% | 31 |
|
|
2020
Q2 | $82.2M | Sell |
131,799
-2,710
| -2% | -$1.54M | 0.86% | 20 |
|
|
2020
Q1 | $65.7M | Sell |
134,509
-20,682
| -13% | -$8.53M | 0.86% | 21 |
|
|
2019
Q4 | $58.3M | Sell |
155,191
-81,823
| -35% | -$27.5M | 0.73% | 32 |
|
|
2019
Q3 | $65.7M | Sell |
237,014
-3,564
| -1% | -$1.05M | 0.89% | 27 |
|
|
2019
Q2 | $75.3M | Buy |
240,578
+99,548
| +71% | +$33.1M | 1.05% | 22 |
|
|
2019
Q1 | $57.9M | Sell |
141,030
-1,491
| -1% | -$614K | 0.83% | 32 |
|
|
2018
Q4 | $53.2M | Sell |
142,521
-32,249
| -18% | -$11.8M | 0.93% | 29 |
|
|
2018
Q3 | $70.6M | Sell |
174,770
-1,761
| -1% | -$670K | 1.07% | 29 |
|
|
2018
Q2 | $60.9M | Sell |
176,531
-1,908
| -1% | -$597K | 0.99% | 32 |
|
|
2018
Q1 | $61.4M | Buy |
+178,439
| New | +$62.1M | 1.02% | 29 |
|
Other funds holding REGN
Rockefeller Capital Management's REGN Position: Q2 2026 in Review
Rockefeller Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 24% in Q2 2026, selling an estimated $4.74M and leaving 21,563 shares worth $13.4M. The position accounts for 0.02% of the portfolio, ranked #616.
Rockefeller Capital Management first reported a position in REGN in Q1 2018 and has held it in 34 quarters since. The position peaked at $106M in Q2 2021. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Rockefeller Capital Management held 21,563 shares of Regeneron Pharmaceuticals worth $13.4M as of Q2 2026.
- Rockefeller Capital Management sold 6,957 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.74M.
- Regeneron Pharmaceuticals made up 0.02% of Rockefeller Capital Management's portfolio in Q2 2026, its #616 holding.
- Rockefeller Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 34 quarters since.
- Rockefeller Capital Management's Regeneron Pharmaceuticals position peaked at $106M in Q2 2021.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.